This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Deal: McKesson Succeeds After New Run at Celesio

NEW YORK (TheStreet) San Francisco drug distributor McKesson (MCK - Get Report) late Thursday, Jan. 23, revived a failed 6.4 billion ($8.8 billion) offer for Germany's Celesio, reeling in 76% from Franz Haniel & Cie Gmbh, a Duisburg, Germany-based family-run conglomerate.

McKesson said it bought the stake at its original offer price and also picked up convertible bonds from New York hedge fund Elliott Management at an unnamed price.

McKesson now has more than the 75% required by German law to treat Celesio as a subsidiary. The company said it now plans on launching an offer to take Stuttgart-based Celesio private.

McKesson's first run at Celesio failed earlier this month when the approach attracted just 72.33% of the target's share capital, shy of the self-imposed 75% threshold and despite sweetening the offer by 0.50 to 23.50 per share at the last minute.

Must Read: Crumbs Sweetens Future With Credit Facility

At the time Haniel only owned slightly over 50% of Celesio and the deal hinged on Elliott's acceptance. However Elliott, which is led by Paul Singer, had said the approach undervalued Celesio. Singer's fund had made a case for breaking up the target, which acts as a European pharmaceutical wholesaler and also runs its own pharmacies.

Legally, suitors are prohibited from taking another shot at a company for a year but there are exceptions, a spokeswoman for Germany's Bafin securities regulator said.

"The bidder can make an application for a waiver and if the target approves it they can make a new offer," said Bafin's Dominika Kula. "The price they paid for the convertible bonds can be used as a component for calculating the new minimum offer price but it doesn't necessarily have to be."

McKesson needs international heft after drugstore giant Walgreen (WAG) scooped up 45% of its U.K. counterpart Alliance Boots GmbH for $6.7 billion in 2012. Boots and Walgreen then strengthened their cooperation with pharmaceutical distributor AmerisourceBergen (ABC) in a March deal that gave them the right to buy up to 23% of the Dublin, Ohio-based distributor.

Then, Dublin, Ohio-based Cardinal Health in December agreed to form a 50/50 generic drug sourcing joint venture with CVS Caremark (CVS) to directly battle Walgreen/Boots and become the biggest wholesaler in the U.S. CVS and Cardinal had been seen as a Celesio suitor.

"The next offer probably won't come in much above that 23.50," wrote NordLB analyst Thorsten Straus in a note. He has a sell rating on the stock.

Celesio shares jumped 5.2%, or 1.25, to trade at 25.26 in Friday morning Frankfurt trading.

Elliott was advised by JPMorgan Chase.

McKesson took legal advice from Linklaters and Wolf Theiss.

Hengeler Mueller's Maximilian Schiessl, Thomas Meurer and colleagues handled legal details for Haniel while Freshfields Bruckhaus Deringer provided counsel to Celesio.

--Written by Andrew Bulkeley In Berlin

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MCK $152.99 1.74%
AAPL $94.27 -0.76%
FB $101.00 1.47%
GOOG $684.12 0.89%
TSLA $143.67 -3.09%


Chart of I:DJI
DOW 15,914.74 -99.64 -0.62%
S&P 500 1,851.86 -0.35 -0.02%
NASDAQ 4,283.5920 +14.8290 0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs